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A B S T R A C T
Background. – Little data are available for infants who started renal replacement therapy before
6 months of age. Because of extra-renal comorbidities and uncertain outcomes, whether renal
replacement therapy in neonates is justified remains debatable.
Methods. – We performed a retrospective analysis of all patients who began chronic peritoneal dialysis
below 6 months between 2007 and 2017 in two tertiary centres. Results are presented as median
(min;max).
Results. – Seventeen patients (10 boys) were included (8 prenatal diagnoses, 6 premies), with the
following diagnoses: congenital anomalies of kidney and urinary tract (n = 9), oxalosis (n = 5), congenital
nephrotic syndrome (n = 2) and renal vein thrombosis (n = 1). Five patients had associated comorbidities.
At peritoneal dialysis initiation, age was 2.6 (0.1;5.9) months, height-standard deviation score (SDS)
1.3 (5.7;1.6) and weight-SDS 1.4 (3.6;0.6). Peritoneal dialysis duration was 12 (2;32) months, and
at peritoneal dialysis discontinuation height-SDS was 1.0 (4.3;0.7) weight-SDS 0.7 (3.2;0.2),
parathyroid hormone 123 (44;1540) ng/L, and hemoglobin 110 (73;174) g/L. During the first 6 months of
peritoneal dialysis, the median time of hospitalisation stay was 69 (15;182) days. Ten patients presented
a total of 27 peritonitis episodes. Reasons for peritoneal dialysis discontinuation were switch to
hemodialysis (n = 6), transplantation (n = 6), recovery of renal function (n = 2) and death (n = 1). After a
follow-up of 4.3 (1.7;10.3) years, 12 patients were transplanted, 2 patients were still on peritoneal
dialysis, 2 patients were dialysis free with severe chronic kidney disease and 1 patient had died. Seven
patients displayed neurodevelopmental delay, of whom five needed special schooling.
Conclusion. – We confirm that most infants starting peritoneal dialysis before 6 months of age will be
successfully transplanted and will have a favourable growth outcome. Their quality of life will be
impacted by recurrent hospitalisations and neurodevelopmental delay is frequent.
C 2020 Société francophone de néphrologie, dialyse et transplantation. Published by Elsevier Masson
SAS. All rights reserved.
Abbreviations: BMI, Body Mass Index; CAKUT, Congenital anomalies of kidney and urinary tract; CKD, Chronic kidney disease; CKD-MBD, Chronic kidney disease–Mineral
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A. Dachy, J. Bacchetta, A.-L. Sellier-Leclerc et al. Néphrologie & Thérapeutique 16 (2020) 424–430. Introduction
Little information is available for infants who started chronic PD
efore 6 months of age. Children who start RRT within the first
onths of life have more clinical complications, an increased risk
f peritonitis and more technical failure of dialysis compared to
hildren who start RRT later [1–5]. Besides, comorbidities are more
revalent in this population with coexisting extrarenal involve-
ent due to primary disease, making prenatal counselling more
omplicated [1–11]. As summarised in Table 1, long-term data
utcomes are scarce, raising the ethical issues whether PD in
eonates is justified and leading to different managements
etween centres [12]. The objective of this retrospective study
as to report the experience of two French tertiary pediatric
ephrology centres on 17 infants who began chronic PD before
 months of age, on a 10-year period, to provide additional
vidence for the discussion.
. Patients and methods
We performed a retrospective analysis of all patients followed
n two tertiary centres (Lyon and Besançon) who began chronic PD
elow 6 months of age between January 2007 and January 2017.
The following clinical data were recorded: term of the
regnancy, biometric data (height, body weight, head circumfer-
nce) at birth, PD initiation, 15 days after PD initiation, every
 months during the first year of PD, and every 6 months until
 years or until the last follow-up on PD. Biometrical parameters
ere normalised as SDS according to chronological age and gender
ccording to French growth reference charts [13]. The surgical
rocedure for PD catheter insertion was described: catheter
lacement, associated omentectomy. The primary diagnosis and
he presence of a prenatal diagnosis were also recorded. Dialysis
as initiated on manual mode (initial volume of 10 mL/kg), with
rogressive increase until 80 to 100 mL. This volume enabled the
se of an automated cycler (Sleep Safe cycler, Fresenius Medical
are AG & Co., Bad Homburg vor der Höhe, Germany). Cycle volume
as gradually increased to 800 mL/m2 before 2 years of age and
400 mL/m2 after 2 years of age, with 5 to 15 cycles per night and
aytime dwell if needed. PD fluid used for night-time cycles was
iocompatible with a neutral pH, bicarbonate buffer, and low
evels of glucose degradation products (Bicavera or Balance,
resenius Medical Care AG & Co., Bad Homburg vor der Höhe,
ermany); for daytime cycles icodextrine (Extraneal, Baxter
ealthcare LTD, Norfolk, England) was used.
Hemoglobin and PTH status before PD start, 3 months after the
eginning of PD, after one year and at last PD follow-up, were
egistered. In the absence of other formula in this age group, the
009 Schwartz formula was used to evaluate the eGFR at the
eginning of PD [14].
Treatment in terms of active vitamin D doses (mg/kg/d),
hosphate binders use and type, EPO week dose (IU/kg/week) and
H treatment if present (mg/kg/week) were recorded before the
eginning of PD, at 3 and 6 months after the PD start, at the end of
D and at the end of the follow-up.
Complications assessment includes incidence and characteris-
ics of peritonitis, catheter complications (exit site infection ESI,
bstruction, leaks and cuff extrusion). Consequences were
eflected by the hospitalisation rate (the number of hospitalisation
swelling, redness, tenderness with or without pathogenic germs
cultured.
If available, data on cardiological ultra-sounds were recorded.
LVH was defined as a left ventricular mass index > 38 g/m2,7
according to the definition of the International Pediatric Peritoneal
Dialysis Network [16]. We used the International Pediatric
Peritoneal Dialysis Network calculator to define the left ventricular
mass index according to height, left ventricular end-diastolic
diameter, posterior wall thickness and intraventricular septal
diastolic thickness (www.pedpd.org). HTN was defined as blood
pressure  95th percentile for age and height according to the
TASK Force on Blood Pressure Control in Children [17].
Final outcomes were defined as transplantation, hemodialysis
switch, PD arrest and/or death. Time before transplantation, height
and weight at the time of transplantation and type of donor were
reported. Graft survival and causes of graft loss were also collected.
Neurodevelopmental outcomes were determined by the clinical
status of patients at the end of the follow-up (whether he was
presenting developmental delay or not) and the type of schooling
(normal schooling or special education).
Statistical analyses were mainly descriptive, and results are
presented as median (range). Paired tests were used to compare
the evolution of the different parameters at the different time
points. Spearman bivariate analyses were performed. A P-value
below 0.05 was considered statistically significant. This retrospec-
tive study was approved by the local IRB (Comité d’éthique des
hospices civils de Lyon, session June 7th 2018). By French law,
retrospective studies do not require a written consent from the
patients/parents but an oral information.
3. Results
3.1. Clinical characteristics
A total of 17 patients (10 boys) began chronic PD before
6 months of age. Their characteristics are reported in
Table 2. Median age at PD start was 2.6 (0.1;5.9) months with
11 infants starting dialysis between 0–3 months.
Median PD duration was 12 (2;32) months and follow-up was
4.3 (0.7;10.3) years. Residual diuresis was observed during PD in
11 patients, whilst 4 patients were completely anuric at PD start,
and data were missing for 2 patients. The eGFR at PD start was 5
(2;17) mL/min per 1.73 m2.
Five out of the 17 patients were moderate to late pre-term and
one was very pre-term (30 weeks of gestation). Eight out of
12 children had a prenatal diagnosis; medical abortion was refused
by parents in 2 cases, and antenatal data were missing for the last
5 cases. The primary diagnosis was: CAKUT (n = 9), oxalosis (n = 5),
congenital nephrotic syndrome (n = 2) and renal vein thrombosis
(n = 1).
Five patients presented at least one associated comorbidity:
lungs hypoplasia in two babies, neurological comorbidities
resulting from perinatal asphyxia in two and Prune-Belly-like
syndrome in one.
3.2. Growth
Median birth weight and height were 3071 (1570;3870) grams
and 48.5 (41.5;51.5) cm, respectively. The median body weight atnd cumulative duration at 6 months and 12 months after PD
nitiation). Peritonitis was defined according to ISPD recommen-
ations [15]: signs and symptoms of peritoneal irritation,
eritoneal cellularity in cloudy effluent > 100 cells/mm3 or a
ositive culture. Catheter ESI was defined as the presence of
urulent discharge from the catheter or marked peri-catheter42PD start was of 4.6 (1.5;5.8) kg and 1.4 (3.6;0.6) SDS. The
median SDS for weight at PD discontinuation was 0.7 (3.2;0.2)
(P = NS from PD initiation), with a median delta SDS for weight
between the beginning of PD and the end of PD of 0.6 (2.4;1.7).
Median height SDS was 1.3 (5.7;1.6) at the start of PD and 1.0
(4.3;0.7) at the end of PD treatment (P = NS). Median delta SDS for5
A. Dachy, J. Bacchetta, A.-L. Sellier-Leclerc et al. Néphrologie & Thérapeutique 16 (2020) 424–430height between the beginning of PD and the end of PD was 0.2
(3.9;4.8). Median SDS BMI was at the beginning of PD 3.3
(4.3;1.0) and 1.7 (3.3;1.0) at the end of PD (P = 0.005).
Sixteen patients required enteral feeding, 11 by gastrostomy
and 5 by nasogastric tube. Gastrostomy were surgically placed at
3.3 (1.4;12.1) months of age, 14 (10;22) days before PD start for
9 patients; it is noteworthy that two patients had a gastrostomy
placed after the beginning of PD (respectively 296 and 465 days
after). One patient had no enteral feeding at all, but also
demonstrated catch-up growth. Three infants received rhGH
because of severe growth retardation.
3.3. Peritoneal access and PD complications
Twenty-nine PD catheters were surgically placed in 17 patients,
with associated omentectomy in 10 infants. Data about omentec-
tomy were missing for 7 patients. The time between catheter
placement and the beginning of PD was 4 (0;22) days.
Six patients required 11 catheter replacements because of
catheter obstruction (n = 3), dysfunction (n = 4), infections (n = 2)
and leakage (n = 2). Of those, one patient needed replacement of
the peritoneal access twice, two patients needed three different
replacements and three patients needed only one catheter
replacement. Nine catheter obstructions occurred in four patients,
resolving after urokinase treatment in eight cases, and surgical
procedure in one case. Four catheter leakages occur in three
infants. Cuff extrusion occurred only once in one patient.
Twenty-seven episodes of peritonitis occurred in 10 infants.
Eight infants were affected by  two episodes, two patients
Klebsiella n = 3). One patient had a peritonitis episode with
multiple bacteria. Three patients had clinical signs and symptoms
of peritonitis with a cloudy effluent and increased effluent
cellularity but a negative culture. In one patient, no data were
found on the involved organism. ESI were found in two patients,
who presented associated peritonitis.
During the first six months of PD, the median number of
hospitalisations was 3 (1;10). Six patients were hospitalised only
once during this time and all the others underwent two to ten
hospitalisations. The total duration of hospitalisation stays was 69
(15;182) days. Most of the reasons for hospital stays were dialysis
initiation with education of parents (n = 7) and infections (n = 10).
Between the 6th and 12th months on PD, the number of
hospitalisations was 3 (1;11) with a total duration of hospitalisa-
tion stays of 25 (1;186) days. The most common cause of
hospitalisation during this period was infections (n = 12) and
clinical complications (dehydration, vomiting, n = 4).
3.4. Anemia and CKD-MBD
The biochemical evolution of patients is summarised in Table
3. Before PD, median PTH levels were 212 (6;799) ng/L,
decreasing to 130 (23;732) ng/L 3 months after the beginning
of PD, and reaching 123 (44;1540) ng/L at the end of PD (P = NS
between PD initiation and the end of PD). Phosphate binders were
prescribed in five patients before the start of PD, data for
3 patients were missing. Only three patients still received
phosphate binders at the end of PD, three data were missing. The
most frequent type of phosphate binders remained calcium
Table 1
Publications on PD in children less than 2 years of age.
Author Ledermann et al. [8] Vidal et al. [1] Chan et al. [10] Van Stralen et al. [4] Hogan et al. [20] Sanderson et al. [5]
Study type Single centre
retrospective
























Year of publication 1999 2012 2016 2014 2018 2019




20 84 9 264 224 1723
Age < 1 year < 1 year < 2 years < 31 days < 2 years < 1 year
Median age at
start of DP




Median follow-up NS 19 months NS 29 months 78 months NS
Death 4 (20%) 8 (10%) 1 (11%) 45 (17%) 29 (13%) 360 (21%)
Transplantation 11 (55%) 33 (39%) 4 (44%) 53 (20%) 171 (76%) 1060 (61.5%)
Shift to dialysis
modality
4 (20%) 18 (21%) 6 (67%) 69 (26%) NS NS
Catch-up growth 100%
Weight SDS 1.6 at PD
start and 0.3 at 2 years
Height SDS1.8 at PD
start and 0.8 at
2 years
23/47 (49%)
Weight SDS2.3 at PD
start and 1.9 at
2 years
Height SDS1.6 at PD
start and 1.5 at
2 years
No
Weight SDS1.32 at PD
start and 1.3 at
2 years but Height
SDS 0.7 at PD start
and 1.45 at 2 years
166 (63%) NS NS
Normal
neurodevelopment
14/16 (87%) NS 4/8 (50%) NS NS NS
NS: non-specified.underwent a single peritonitis episode and seven patients did
not present any peritonitis. One peritonitis episode occurred every
7.6 months–patient. Most frequent organisms were Gram-positive
cocci (n = 13; Staphylococcus aureus n = 7; coagulase-negative
Staphylococcus n = 5; Streptococcus n = 1), followed by Gram-
negative bacillus (n = 9, Escherichia Coli n = 4, Pseudomonas n = 2,426carbonate. One patient with severe hyperparathyroidism re-
quired calcium carbonate and sevelamer. Seven patients received
active vitamin D analogs at the start of PD with a median daily
dose of alfacalcidol of 0.06 (0.02;0.30) mg/kg. Six patients were
still treated at the end of the PD with a median daily dose of 0.07
(0.02;0.20) mg/kg.
A. Dachy, J. Bacchetta, A.-L. Sellier-Leclerc et al. Néphrologie & Thérapeutique 16 (2020) 424–430Median hemoglobin levels at PD start were 94 (60;191) g/L, and
110 (73;174) g/L at the end of PD (P = NS). Before PD, 12 patients
were receiving EPO, with a median of 369 (179;1235) UI/kg per
week. One patient was not receiving EPO and data were not
available for 4 patients. At the end of PD, EPO median dose was 333
(163;1250) UI/kg per week (12 treated patients, 2 non-treated
patients and 3 missing data).
3.5. Cardiovascular impact
At the beginning of PD, 6 patients had an echocardiography. Of
those, five patients demonstrated LVH with a median left
ventricular mass index of 55 (34;63) g/m2.7. Three over 5 patients
with LVH received anti-hypertensive therapies (one missing data)
and one patient displayed HTN. After 3 months on PD, 8/11 patients
assessed for cardiovascular function displayed LVH with a median
left ventricular mass index of 66 (34;108) g/m2.7. Four over
8 patients had anti-hypertensive therapy and one patient had HTN.
After one year on PD, 10/13 patients who had cardiovascular
evaluation displayed LVH and a median left ventricular mass index
of 59 (37;94) g/m2.7 with associated HTN for 7/10 patients and
anti-hypertensive treatment in 5/10 patients (one missing data). At
the end of PD, among the 11 patients who underwent an
echocardiography, ten still had LVH with a median left ventricular
mass index of 72 (35;170) g/m2.7, 5/10 having HTN and 2/
10 receiving anti-hypertensive therapies (one missing data).
3.6. Neurodevelopmental outcomes
Data concerning the head circumference SDS at PD start were
collected in 11 patients with a head circumference SDS of –1.0 (–
4.9;1.3), decreasing at –1.1 (–5.0;0.4) after 6 months of PD to –1.2
(–3.6;0.7) one year after PD start (P = NS) between PD initiation
and one year after PD initiation. Data were insufficient to assess the
cranial perimeter at the end of PD and beyond this date.
Neurological status of the 16 surviving patients was reviewed.
After a follow-up of 4.3 (1.7;10.3) years, seven patients displayed
neurodevelopmental delay with five patients needing special
schooling. Among those seven patients, four presented with severe
extra-renal comorbidities, and notably two had perinatal asphyxia
with hypoxia. One perinatal asphyxia occurred in a context of
congenital nephrotic syndrome with neonatal vascular stroke
resulting in right hemiplegia. One patient presented pulmonary
hypoplasia and one patient presented a Prune-Belly-like syn-
drome. The last three patients with neurodevelopmental delay had
no associated extra-renal comorbidities.
3.7. Long-term outcomes
The causes of PD discontinuation were the following:
 switch to hemodialysis (n = 6);
 transplantation (n = 6);
 recovery of renal function (n = 2);
 death (n = 1).
Reasons for hemodialysis shift were oxalosis (n = 4), catheter
dysfunction (n = 1) and recurrent peritonitis and pleural effusion
(n = 1). Oxalosis patients (n = 5) underwent simultaneous hemo-






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































42months on PD. Two patients with primary hyperoxaluria were
transplanted while they were still on simultaneous hemodialysis
and PD, as previously reported [18].
After a follow-up of 4.3 (1.7;10.3) years, 12 patients had
received a kidney transplant, 2 patients were still on PD, 2 patients
had spontaneous recovery of renal function (after 2.2 and7
A. Dachy, J. Bacchetta, A.-L. Sellier-Leclerc et al. Néphrologie & Thérapeutique 16 (2020) 424–4307.6 months of PD with respectively eGFR 45 mL/min per 1.73 m2
one month post-discontinuation and 23 mL/min per 1.73 m2 four
months after discontinuation). One patient died after 12 months on
PD and 2.1 years of follow-up, shortly after central venous catheter
positioning because of Staphylococcus sepsis.
Median time between PD start and transplantation was 22
(8;32) months and median age at first transplantation was 25
(12;42) months with a median body weight of 11.3 (8.6;13.3) kg
and a median height of 83 (72.5;87) cm. All kidney transplants
were coming from deceased donors. Two patients lost their graft
because of venous graft thrombosis, as previously reported
[19]. Long-term outcomes are summarised in Table 4.
4. Discussion
Even if the incidence of ESRD in children less than 4 years is low
(5.2 per million age-related inhabitants in France) [20], the
initiation of chronic PD in infants below 6 months represents a
challenge and dialysis in neonates is still debated [21]. In a recent
study, which focused on maintenance dialysis that was started
before one year of age, a younger age at RRT start was found to be a
significant risk factor for death. This risk fell by 5% for each month
that the infants aged [22]. Ethical issues related to the high
morbidity rate, the increased risk of peritonitis and the overall
fragility of infants starting RRT at a young age need to be weighed
against the important progress made in this field over the past
years, allowing better chances of survival. In our centre, the
decision process from whether or not to start dialysis is mainly
children starting RRT before 2 years of age [1,8,20]. In terms of
growth, our report shows a slight increase of median height SDS
during PD. This is consistent with the data published by others
[1,4,6,8,10]. In contrast, a Chinese cohort of nine children starting
RRT below 2 years of age showed a satisfactory weight gain but a
decline in height SDS from 0.7 SDS at PD initiation to 1.4 SDS at
the end of follow-up [10]. Only three patients were treated by rGH
at the end of PD in our cohort; we believe that optimisation of
nutritional status is most of the time sufficient to ensure growth
catch-up in this age group [8]. However, some children will have to
be treated with rGH if the nutritional management is insufficient,
as recently reviewed in the European guidelines on the use of rhGH
in pediatric CKD [23]. In a randomised study collecting 16 patients
less than 24 months of age with severe CKD stage 3–4, seven
patients were enterally fed and 80% of them had recommended
daily calories, GH treated patients showed significantly higher
length gains (14.5 versus 9.5 cm/year with mean height SDS +1.43
versus 0.11) [24]. Concerning weight gain, we found a steady
increase in weight parameters during the time on PD. In our cohort,
11/17 patients were fed enterally by gastrostomy, which appeared
to be the best way of enteral feeding in young children on chronic
PD [25]. Only one patient had no enteral feeding at all (refused by
parents), despite severe initial intra-uterine growth retardation,
but growth was relatively correct provided a very intensive
nutritional care (mean height SDS 5.7 at the start of PD to 1.8
after 23 months on PD; mean weight SDS 3.4 at the start of PD to
1.7 at the end of the 23 months on PD). However, this child
displayed uncontrolled severe secondary hyperparathyroidism
and severe orality troubles.
Table 4
Flow chart: long-term outcomes.
Outcome Ongoing PD Switch to HD Transplantation Renal function recovery Death
Number of patients 2 6 6 2 1
Median follow-up (years) 2.0 (1.7;2.3) 6.8 (4.3;10.3) 3.0 (2.8;10.1) 4.4 (2.2;6.7) 2.2
Height SDS 1.5 (2.8;0.3) 2.0 (2.5;0,0) 1.1 (2.7;0.1) 0.9 (1.6;0.2) 3.9












Evolution With 1 graft loss
(early thrombosis)
1 graft loss 2 CKD cases
Table 3
Biochemical evolution of patients during PD treatment.
PD initiation M3 M12 PD withdrawal End of follow-up
Serum PTH (ng/L) 212 (6;799) 130 (23;732) 163 (18;957) 123 (44;1540) 91 (32;378)
Hemoglobin (g/L) 94 (60;191) 107 (70;136) 121 (88;150) 110 (73;174) 114 (84;147)
Serum phosphate (mmol/L) 2.36 (0.64;4,06) 1.86 (1.30;2.71) 1.70 (1.02;2.43) 1.65 (0.66;2.33) 1.34 (0.59;1,51)
Serum phosphate SDS for age 1.5 (11.0;13.9) 0.3 (6.2;4.5) 0.4 (4.0;3.1) 0.8 (9.3;2.6) 1.6 (6.0;1.0)
EPO (UI/kg per week) 369 (0;1235) 355 (0;643) 350 (0;659) 333 (0;1250) 293 (0;400)
Number of GH treated patients 0 0 0 2 3
Number of patients receiving phosphate binder
Sevelamer 0 1 1 1 1
Calcium carbonate 5 4 5 3 1
Total treated patients 5 4 5 3 1
EPO: erythropoietin.based on family information and multi-professional team ethical
discussions about the main factors affecting the expected quality of
life, such as extra-renal comorbidities and/or anuria [9,12,21].
The majority of patients in our study were successfully
transplanted, with favourable growth. This is consistent with
the results found by others, which confirmed the good outcomes of428A significant increase in BMI was found in our study from
3.3 SDS at PD beginning to 1.7 SDS at the end of PD. None of the
patients had a BMI > 2 SDS. In Brady’s study evaluating carotid
intima-media thickness of 101 children aged 2–18 years with mild
to moderate CKD during 12 months of follow-up, dyslipidemia was






























































A. Dachy, J. Bacchetta, A.-L. Sellier-Leclerc et al. Néphrologie & Thérapeutique 16 (2020) 424–430ith increased intima-media thickness, although no direct
orrelation was found between BMI and increased carotid
ntima-media thickness [26]. According to the study of Bonthuis
nd al., who evaluated the prevalence of obesity and underweight
mong 4474 patients less than 16 years on RRT in 25 European
ountries, the prevalence of underweight was 3.5%, whereas 12.5%
ere obese [27]. As obesity seems more prevalent than under-
eight in European children on RRT, it seems necessary to avoid a
oo important catch-up weight gain in these youngest children, so
s to avoid to worsen the cardiovascular risk in the long term
27]. Indeed, a significant proportion of our patients on PD already
isplayed LVH, and previous works have shown that the control of
rterial hypertension in children on PD is far from optimal [4,6].
As it was previously reported, we found an increased risk of
eritonitis and PD catheter complication in infants [1,6,8,28]. Com-
ared to previous reports on the subject, our series has an
mportant proportion of patients with hyperoxaluria (our unit is a
eference centre for this disease), these patients are known to
isplay severe growth retardation, malnutrition and systemic
isease [29]. Oxalosis (n = 4) was the major cause of PD
iscontinuation, followed by catheter dysfunction (n = 1) and
ecurrent peritonitis (n = 1).
As described in the two large studies evaluating survival among
nfants less than 1 year of age, who initiated chronic PD [6,30],
ost of the infants terminated dialysis for transplantation. This is
onsistent with the results of the Italian, the French and the GOSH
eries [1,8,20]. However, they reported a 4-fold greater mortality
han in older children and mortality rates were 2-fold higher in
nfants who had at least one medical comorbidity such as
rematurity, hypoxic-ischemic encephalopathy, Wilm’s tumour,
ulmonary hypoplasia [1]. Interestingly, Sanderson found no
ignificant difference in the risk of mortality based on age of
ialysis initiation in the USA [30], as opposed to Vidal who found a
% lower risk of death per month of later initiation [1]. Neverthe-
ess, in both studies, infectious complications remain the main
ause of death in younger children on PD [1,31,32]. In our cohort,
ne patient with hyperoxaluria died from an infectious complica-
ion.
Concerning neurodevelopmental outcomes, a Chinese cohort of
ine children starting RRT below 2 years of age showed a
evelopmental delay in 44% of children [10]. In our study, 7/
6 patients displayed neurodevelopmental delay with five patients
eeding special schooling. Of those, four patients had associated
omorbidities, which are known to be strongly associated with
oor neurodevelopmental outcomes [15]. A positive neurodeve-
opmental outcome after prolonged period on PD is however
requently observed as reported by Lederman [8], who showed
ormal developmental scores 1 and 4 years after PD start in
4 infants who started PD before 3 months of age: in this series,
9% of the school-aged children attended normal school.
bviously, a longer follow-up and an evaluation in early adulthood
ould be crucial, but data are missing, and in the course of CKD in
nfancy, many events may occur between the first year of age and
ate teenage, all being able to further compromise developmental
utcomes.
We found no significant differences in outcomes for growth,
eurological development, infections, catheter-related complica-
ions, extra-renal comorbidities and kidney transplant between
nuric infants (n = 4) compared to those with residual diuresis.
We have to acknowledge some limitations to this study, mainly
5. Conclusion
We focused our study on the outcomes of infants starting PD
before 6 months of age and aimed to provide new data in this
specific population. Our study suggests that with an intensive
management, and close nutritional support, PD in infants can
provide a favourable outcome concerning growth, development
and transplantation [8]. However, those youngest infants are at
increased risk of PD catheter complication and peritonitis with
prolonged hospitalisations, having a direct impact on their quality
of life. Extra-renal comorbidities remain predictive factor of poor
prognosis and need to be considered when counselling parents.
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